Over 6,000 mumps cases were reported in the US during 2016 by the CDC, the highest in a decade. While earlier routine vaccine programs drastically reduced rates of mumps and measles, these diseases have made a comeback – triggering the hunt for new strategies in effective drug development.
Industry experts from Covance and Euroimmun will cover critical measles and mumps vaccination development issues including:
- Concomitant testing needs: any company developing pediatric vaccines for routine use will need to test for measles infection and protection during the clinical evaluation phase
- How to measure immunity: examining the challenge of differentiating natural antibodies (from natural infection) from vaccine elicited ones
- Immune profiling of human immune response: measles antibodies as components of serological panels to evaluate immune response before and after treatment
Rolando Pajon, PhD, Lead Scientist, Vaccine and Novel Immunotherapeutics, Covance
Rolando Pajon, PhD, completed his studies from the University of Havana Cuba, and went onto leading multi-disciplinary teams for nearly two decades. With more than 20 years of experience in research, development and evaluation of vaccines and Immunotherapeutics, he now leads the Covance Vaccine and Novel Immunotherapies Laboratory Solutions team for the design, qualification, validation, and execution of complex immunological assays. Rolando and his team represent Covance’s reach at providing strategic technical leadership in developing scientific approaches to clients and sponsors on a global scale.Message Presenter
Oliver Sendscheid, PhD, Scientific Affairs Director, EUROIMMUN US, Inc.
Oliver Sendscheid, PhD, joined EUROIMMUN in Luebeck, Germany after studying Biology at the University of Bonn, followed by his PhD studies at the Max Planck Institute for Molecular Biomedicine in Muenster, Germany. As Product Manager at EUROIMMUN, Dr. Sendscheid specialized in autoimmune and infection diagnostics. In 2016, he joined the U.S. subsidiary as Scientific Affairs Director, where he represents the scientific arm of the U.S. subsidiary and manages high-level scientific relationships with key opinion leaders across the United States.Message Presenter
Who Should Attend?
Chief Medical Officers, Chief Scientific Officers, plus senior level professionals in the following fields:
- Vaccine Developers
- Diagnostic Laboratories
- Immune Profiling Laboratories
- Personalized Medicine
- Translational Medicine
Covance Inc., the drug development business of Laboratory Corporation of America Holdings (LabCorp) headquartered in Princeton, New Jersey, USA, is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®.
Our unique perspectives, built from decades of scientific expertise and precision delivery of the largest volume of drug development data in the world, helps our clients identify new approaches and anticipate tomorrow’s challenges as they evolve. Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Information on Covance’s solutions can be obtained through its website at www.covance.com.
EUROIMMUN US, Inc.
EUROIMMUN US, Inc., a subsidiary of EUROIMMUN, is a world leader in the field of medical diagnostics. EUROIMMUN established itself as an industry innovator with its unique IFA BIOCHIP Mosaic technology and has successfully introduced new technologies such as ELISA, Western & Immunoblot assays since its inception in 1987. The company’s global success is attributed to its strategic product development in which designer antigens, as well as patented and licensed technologies, play an important role. EUROIMMUN is consistently expanding its product offerings with new assays to aid in the detection of antibodies associated with autoimmune and infectious disease.